Intellia Therapeutics (NTLA) Misses Q2 EPS by 5c

Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($1.33), $0.05 worse than the analyst estimate of ($1.28). Revenue for the quarter came in at $14.03 million versus the consensus estimate of $9.42 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Freedom Broker Starts Copart (CPRT) at Buy
• Investing.com’s stocks of the week